Navigation Links
Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board

Cell therapy industry consultant Lee Buckler appointed to Regenerative Medicine editorial board.

Vancouver, BC (PRWEB) August 27, 2008 -- The Cell Therapy Group ( announced today the appointment of its principle consultant, R. Lee Buckler, to the Editorial Board of the journal Regenerative Medicine.

Published by Future Medicine, Regenerative Medicine has become a premier journal for a fast growing community of specialists addressing the important challenges and advances in the commercializing of cell therapy research and regenerative medicine.

Under the aegis of Dr. Chris Mason who heads the Regenerative Medicine Bioprocess Group in the Advanced Centre for Biochemical Engineering at University College London (UCL), the journal features an editorial board of over 70 leading international experts drawn from the leading forces in industry and academia.

Mr. Buckler has served many capacities in the regenerative medicine sector to-date including Executive Director of the International Society for Cellular Therapy (ISCT), Operations Manager of Malachite Management, Founder and Editor-in-Chief of Cell Therapy News, business development and marketing communications at Progenitor Cell Therapy and DomaniCell, and communications at Amorcyte, Inc. Lee also served on the Editorial Advisory Board of BioProcess International. Lee heads business and commercial consulting services at the Cell Therapy Group and also blogs at [ __title__ Cell Therapy Blog].

"I am pleased to have an opportunity to contribute in this way," says Lee, "to an industry poised - I believe in the short term - to bring significant, new therapeutic and commercial successes to market. The journal, Regenerative Medicine, in addition to great science offers a unique focus on commercialization and industry challenges that will be critical to the success of this field. It is on those issues for the cell therapy sector that I look to contribute to the journal and the industry as a whole."

the Cell Therapy Group
Cell Therapy Group (CTG) is a consultancy for the commercial side of the cell therapy and regenerative medicine sector serving therapeutic, device, and reagent companies, investors, publishers, and other consultants with marketing, communications, business development, market analysis & research, management, strategic planning and other types of services related to the commercialization of cell therapies, regenerative medicine products, and ancillary support products and services. For more information, see [ __title__ Cell Therapy Group Website].

Regenerative Medicine
Indexed on MEDLINE and ISI Science Citation Index, Regenerative Medicine was recently recognized by The Association of Learned and Professional Society Publishers as joint winner of the 2006 ALPSP/Charlesworth Award for Best New Journal. This prestigious international award is presented annually to the best new journal across a wide range of disciplines. For more info, see


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
2. MUSC Spin-Off Company to Test Regenerative Wound Healing Gel
3. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
4. Organogenesis, Inc. to Develop Regenerative Medicine Therapies for U.S. Military Battlefield Injuries
5. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
6. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
7. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
10. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
11. Agendia Joins the Personalized Medicine Coalition (PMC)
Post Your Comments:
Related Image:
Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):